Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

India’s top scientific minds discuss preparedness against emerging health threats

Discussions during the meeting focused on strengthening India’s preparedness against zoonotic diseases and climate-sensitive health challenges

Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion

Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26

Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment

Solara's strong Q4 lifts FY26 finish but ibuprofen drag forces strategic review

The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million